GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » Institutional Ownership

COCP (Cocrystal Pharma) Institutional Ownership : 7.80% (As of Dec. 15, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cocrystal Pharma's institutional ownership is 7.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cocrystal Pharma's Insider Ownership is 43.85%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cocrystal Pharma's Float Percentage Of Total Shares Outstanding is 76.15%.


Cocrystal Pharma Institutional Ownership Historical Data

The historical data trend for Cocrystal Pharma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Institutional Ownership Chart

Cocrystal Pharma Historical Data

The historical data trend for Cocrystal Pharma can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 4.90 4.91 4.91 4.91 4.93 5.03 5.03 5.04 5.04 5.04

Cocrystal Pharma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cocrystal Pharma Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Executives
Fred Hassan director C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al director, 10 percent owner 4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr director 4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi director, 10 percent owner 1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady director 19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin officer: Interim CFO 4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale officer: INTERIM CFO 1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers officer: CHIEF MEDICAL OFFICER C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott officer: GENERAL COUNSEL AND SECRETARY 1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler director 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block director
Hsiao Jane Ph D director 4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027

Cocrystal Pharma Headlines

From GuruFocus

Cocrystal Pharma Inc at LD Micro Main Event Transcript

By GuruFocus Research 03-02-2024

Cocrystal Pharma Inc Virtual Investor Summit Transcript

By GuruFocus Research 03-02-2024